Cara Q4 2020 Earnings Report
Key Takeaways
Cara Therapeutics reported a net income of $78.9 million for the fourth quarter of 2020, compared to a net loss of $28.6 million for the same period in 2019. Total revenue was $112.1 million, primarily consisting of license and milestone fees revenue.
FDA accepted the filing of the NDA for KORSUVA Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Entered into a license agreement with Vifor for commercializing KORSUVA Injection in the U.S.
Completed full enrollment in the KARE Phase 2 dose-ranging trial of Oral KORSUVA for atopic dermatitis.
Initiated a Phase 2 trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in patients suffering from Notalgia Paresthetica.
Cara
Cara
Forward Guidance
Cara expects that its existing unrestricted cash and cash equivalents and available-for-sale marketable securities as of December 31, 2020 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into 2023, without giving effect to any potential milestone payments or potential product revenue under existing collaborations.